The Rh-α<sub>4</sub>β<sub>7</sub>-VRC01 combination significantly delays SHIV<sub>AD8-EO</sub> acquisition.
- Giulia Calenda (635216)
- Ines Frank (215433)
- Géraldine Arrode-Brusés (648084)
- Amarendra Pegu (5166344)
- Keyun Wang (1471393)
- James Arthos (206277)
- Claudia Cicala (206269)
- Kenneth A. Rogers (430431)
- Lisa Shirreff (6694178)
- Brooke Grasperge (528109)
- James L. Blanchard (241468)
- Stephanie Maldonado (6694181)
- Kevin Roberts (225287)
- Agegnehu Gettie (215440)
- Francois Villinger (109159)
- Anthony S. Fauci (73431)
- John R. Mascola (229761)
- Elena Martinelli (206264)
DOIAbstract
(A) Schematic of the study procedures (B-C) The concentrations of VRC01 (B) and Rh-α4β7 (C) were measured in plasma for the first 8 weeks after initiation of treatment. VRC01 levels were below the protective concentration in GH63 and KT57 (orange and green in B, respectively). BL: right before the first infusion with VRC01 and Rh-α4β7 Solid colored line (red for VRC01 and blue for Rh-α4β7) represent the mean of all macaques. (D) Log viral RNA (copies/ml) in plasma are shown from the time of the first challenge (week 0). (E) Kaplan-Meier curves generated with time to first viral detection in plasma are shown. Curves were compared with the Log-rank test (* p-value = 0.016; Gehan-Breslow-Wilcoxon test p = 0.015) α+ T cell counts (G) are shown....
Add to ORKG